Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 13, 2014 07:00 ET | Source: Lipocine Inc.

Lipocine Announces Positive Top-Line Results in Phase 2a Study of LPCN 1111

Candidate For Once Daily Dosing Single daily oral dose provides testosterone levels in the eugonadal range Demonstrated good dose response Steady state achieved by day 14 No subject...
September 24, 2014 08:30 ET | Source: Lipocine Inc.

Lipocine Announces Positive Top-Line Results in Its Phase 3 Study of LPCN 1021 for Oral Testosterone Replacement Therapy

Met primary efficacy endpoint by successfully restoring testosterone levels to the normal range in 88% of the subjects Lower limit of the 95% confidence interval was 82% 85% of the...
September 23, 2014 16:00 ET | Source: Lipocine Inc.

Lipocine to Host Conference Call and Webcast to Discuss Top-Line Results From the Phase 3 Study of LPCN 1021

SALT LAKE CITY, Sept. 23, 2014 (GLOBE NEWSWIRE) -- Lipocine Inc. (Nasdaq:LPCN), a specialty pharmaceutical company, today announced that the Company will host a conference call and webcast tomorrow,...
September 08, 2014 16:00 ET | Source: Lipocine Inc.

Lipocine Announces First Patient Dosed in Phase 1 Study in Pregnant Women of LPCN 1107, Potentially the First Oral Product for the Prevention of Preterm Birth

SALT LAKE CITY, Sept. 8, 2014 (GLOBE NEWSWIRE) -- Lipocine Inc. (Nasdaq:LPCN), a specialty pharmaceutical company, today announced the first patient was dosed in a Phase 1 study in pregnant women of...
August 13, 2014 16:00 ET | Source: Lipocine Inc.

Lipocine Announces Financial and Operational Results for the Second Quarter of 2014

SALT LAKE CITY, Aug. 13, 2014 (GLOBE NEWSWIRE) -- Lipocine Inc. (Nasdaq:LPCN), a specialty pharmaceutical company, today announced financial results for the quarter ended June 30, 2014, as well as...
July 15, 2014 16:00 ET | Source: Lipocine Inc.

Lipocine Announces Issuance of U.S. Patent for LPCN 1021

SALT LAKE CITY, July 15, 2014 (GLOBE NEWSWIRE) -- Lipocine Inc. (Nasdaq:LPCN), a specialty pharmaceutical company, today announced that the United States Patent and Trademark Office (USPTO) has issued...
June 30, 2014 16:45 ET | Source: Lipocine Inc.

Lipocine Added to Russell Microcap Index

SALT LAKE CITY, June 30, 2014 (GLOBE NEWSWIRE) -- Lipocine Inc. (Nasdaq:LPCN), a specialty pharmaceutical company, today announced that it was added to the Russell Microcap Index when Russell...
May 29, 2014 16:15 ET | Source: Lipocine Inc.

Lipocine to Present at the Jefferies 2014 Global Healthcare Conference

SALT LAKE CITY, May 29, 2014 (GLOBE NEWSWIRE) -- Lipocine Inc. (Nasdaq:LPCN), a specialty pharmaceutical company, today announced today announced Mahesh Patel, President and CEO, and Morgan Brown,...
May 27, 2014 16:15 ET | Source: Lipocine Inc.

Lipocine Announces First Patient Dosed in Phase 2a Study of LPCN 1111, a Novel Testosterone Ester for Oral Testosterone Replacement Therapy

SALT LAKE CITY, May 27, 2014 (GLOBE NEWSWIRE) -- Lipocine Inc. (Nasdaq:LPCN), a specialty pharmaceutical company, today announced that the first patient has been dosed in a Phase 2a clinical study of...
May 15, 2014 08:30 ET | Source: Lipocine Inc.

Lipocine Announces Successful Phase 1 Results With LPCN 1107, Potentially the First Oral Product for the Prevention of Preterm Birth

Significant absorption upon oral dosing of LPCN 1107 Good dose response demonstrated LPCN 1107 oral steady state 400mg BID exposure is about 55% of weekly 250mg IM product SALT LAKE...